Amgen Inc. (AMGN) Collaborates on Ending Anti-OX40 Clinical Studies

<p>We recently compiled a list of the <a href="https://www.insidermonkey.com/blog/11-best-kid-friendly-stocks-to-invest-in-1712032/?singlepage=1">11 Best Kid-Friendly Stocks to Invest In</a>. Amgen Inc. (NASDAQ:AMGN) is one of the best kid-friendly stocks on our list.</p>
<p>On March 3, TheFly reported that Kyowa Kirin Co., Ltd. disclosed that it is discontinuing all ongoing clinical trials involving rocatinlimab, an experimental anti-OX40 monoclonal antibody that was previously being tested for moderate-to-severe asthma, prurigo nodularis, and moderate-to-severe atopic dermatitis. The action follows a scheduled safety assessment within the global development program conducted with Amgen Inc. (NASDAQ:AMGN). The latest review highlighted newly emerging safety issues, including additional malignancy cases with potential viral or immune associations, such as confirmed and suspected instances of Kaposi’s sarcoma.</p>
<p>Although the total number of malignancy events across studies remained below expected background levels, the pattern of these cases raised scientific concerns linked to OX40 pathway activity. After evaluating the accumulating safety evidence, the companies determined that possible risks could exceed the anticipated therapeutic benefits for patients enrolled in the trials. Investigators and regulatory authorities are being informed, and once participants complete mandatory safety monitoring visits, the clinical studies will be formally ended while the full dataset undergoes further analysis.</p>
<p>Furthermore, Amgen Inc. (NASDAQ:AMGN) announced on March 4 that its Board has approved a cash dividend of $2.52 per share for the second quarter of 2026. The stockholders listed at the end of trade on May 15, 2026, will get the payout on June 5, 2026.</p>
<p>Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers, develops, and manufactures medicines to treat serious diseases, including cancer, heart disease, and inflammatory conditions.</p>
<p>While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the<a href="https://www.insidermonkey.com/blog/three-megatrends-one-overlooked-stock-massive-upside-1548959/"> best short-term AI stock</a>.</p>
<p>READ NEXT: <a href="https://www.insidermonkey.com/blog/33-stocks-that-should-double-in-3-years-1709437/">33 Stocks That Should Double in 3 Years</a> and <a href="https://www.insidermonkey.com/blog/15-stocks-that-will-make-you-rich-in-10-years-1711641/">15 Stocks That Will Make You Rich in 10 Years</a> </p>
<p>Disclosure: None. <a href="https://news.google.com/publications/CAAqLQgKIidDQklTRndnTWFoTUtFV2x1YzJsa1pYSnRiMjVyWlhrdVkyOXRLQUFQAQ?hl=en-US&amp;gl=US&amp;ceid=US%3Aen">Follow Insider Monkey on Google News</a>.</p>